Head-to-head evidence
Hrain anti-BCMA CAR-T vs JY232
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: CAR-T cell therapy · full Multiple Myeloma pipeline
Hrain anti-BCMA CAR-T
Developed by Hrain Biotechnology Co., Ltd.
NCT03093168 · Phase 1 · status unknown
This is a small, single-arm, open-label safety study with no control group, so it cannot show whether the therapy works better than an alternative. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The published five-year analysis reports 49 treated patients, more than this study's originally listed enrollment.
Next expected readout: December 2026 · NCT06793449 (registry estimate)
JY232
Developed by Shenzhen Genocury Biotech Co., Ltd.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2028 · NCT07336823 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Hrain anti-BCMA CAR-T's landscape · JY232's landscape